CHRONIC COUGH

WELL PHARMA MEDICAL RESEARCH.

New Study Call-In Information Sheet

Sex

Age

# Visits

Payment

Diagnosis

# Subjects

F/M

At least 18 years

14

Visit -$100(visit 4,5,6 extra $75)

TC – $25 Disc $100 Unsc – $50

Chronic Cough

8

Protocol #    MK-7264-027-01

Title:  A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study

To Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with Chronic Cough

(PN027)

Coordinator: Guido Elias

Type of Volunteer:  Adults with Chronic Cough

Length of Study:   54 Weeks (379 Days)

Specific Inclusions: 

  • Chest radiograph or computed tomography scan of the thorax (within 5 years of screening Visit)
  • Have chronic cough for ≥1 year and a diagnosis of refractory chronic cough or unexplained chronic cough.
  • Women and men at least 18 years of age at the time of informed consent.

Specific Exclusions: 

  • Current smoker.
  • History of upper or lower respiratory tract infection or recent clinically significant
  • change in pulmonary status within 4 weeks of Screening/Visit 1
  • History of chronic bronchitis, defined as a cough that produces a clinically significant amount of sputum (greater than approximately 1 tablespoon of phlegm) that occurs every day for at least 3 months in a row, with those periods occurring at least 2 years in a row.
  • Individuals who are currently taking an angiotensin converting enzyme inhibitor or have taken an angiotensin converting enzyme inhibitor within 3 months of Screening/Visit 1.
  • Screening systolic blood pressure >160 mm Hg or a diastolic blood pressure >90 mmHg.